Clinical Trial Update: Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating the safety and tolerability of RX001 in patients with KRAS-mutant advanced non-small cell lung cancer; the study status is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RX001

Snippet

Sponsor: GeneCraft Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: NOT_YET_RECRUITING